View live charts, options flow & technicals for Revvity, Inc. →
Open Dashboard
Revvity, Inc. (RVTY) is a healthcare company in the diagnostics & research industry with $2.91B in trailing revenue trading at a 72.3× trailing P/E — analyst consensus: buy.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Key Statistics
Market Cap
$16.86B
Revenue (TTM)
$2.91B
EPS (TTM)
$2.09
EPS (Fwd est.)
$5.89
Employees
11,000
Trailing P/E
72.30
Forward P/E
25.64
PEG Ratio
0.73
Price / Sales
5.79
Price / Book
2.33
EV / EBITDA
21.90
Beta (5Y)
1.09
Analyst Consensus
Consensus
Buy
Analyst Price Target
-14.6% downside
Target: $129.00
Annual Revenue & Net Income
RevenueNet Income
'22
$3.31B
$570.00M
'23
$2.75B
$690.00M
'24
$2.76B
$270.00M
'25
$2.86B
$240.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$1.41
$1.22
Beat (+15.9%)
May 2026
$1.06
$1.01
Beat (+4.5%)
Feb 2026
$1.70
$1.58
Beat (+7.8%)
Oct 2025
$1.18
$1.14
Beat (+3.6%)
Next Earnings Report
Revvity, Inc. is next expected to report earnings on 26 Oct 2026.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectiou…
What is RVTY's market cap?
Revvity, Inc. has a market capitalization of approximately $16.86B.
What is RVTY's P/E ratio?
Revvity, Inc. trades at a trailing P/E ratio of 72.3x and a forward P/E of 25.6x, which is above the broad market average of ~25x.
How much revenue does RVTY generate?
Revvity, Inc. generated $2.91B in trailing 12-month revenue.
What do analysts say about RVTY?
The analyst consensus rating for Revvity, Inc. is buy, with a mean price target of $129.00. That implies -14.6% upside from the current price.
When does RVTY report earnings?
Revvity, Inc. is next scheduled to report earnings on 26 Oct 2026.
Does RVTY pay a dividend?
Yes. Revvity, Inc. pays a dividend with a current yield of 0.19%, at an annual rate of $0.28 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Revvity, Inc. on Apsis Markets.